An update on lipidomics: Progress and application in biomarker and drug development

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Substantial progress has been made in the application of lipidomics in biomarker discovery and drug development, as well as in a variety of other areas. In particular, the number of published studies reporting the quantitation and analysis of low-abundance lipid molecular species has greatly increased. It can be anticipated that many of the biochemical mechanisms underlying metabolic syndromes and other lipid-related diseases will be identified through these methods. Importantly, lipid markers diagnostic of the onset, progression, or severity of these diseases as well as evaluation of drug efficacy and safety will be discovered as the ability to detect low-abundance lipid molecular species improves. An update of technical developments within the field of lipidomics from 2006 to the present is provided, along with a brief discussion of its applications in biomarker and drug development.

Original languageEnglish (US)
Pages (from-to)586-591
Number of pages6
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number6
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Biomarkers
Lipids
Pharmaceutical Preparations
Drug Evaluation
Drug Discovery
Safety

Keywords

  • Biomarker
  • Drug discovery
  • Electrospray ionization mass spectrometry
  • Lipidomics
  • Pharmacolipidomics
  • Shotgun lipidomics

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

An update on lipidomics : Progress and application in biomarker and drug development. / Han, Xianlin.

In: Current Opinion in Molecular Therapeutics, Vol. 9, No. 6, 01.12.2007, p. 586-591.

Research output: Contribution to journalReview article

@article{9104a724cf854ac7a68640bc664d1e23,
title = "An update on lipidomics: Progress and application in biomarker and drug development",
abstract = "Substantial progress has been made in the application of lipidomics in biomarker discovery and drug development, as well as in a variety of other areas. In particular, the number of published studies reporting the quantitation and analysis of low-abundance lipid molecular species has greatly increased. It can be anticipated that many of the biochemical mechanisms underlying metabolic syndromes and other lipid-related diseases will be identified through these methods. Importantly, lipid markers diagnostic of the onset, progression, or severity of these diseases as well as evaluation of drug efficacy and safety will be discovered as the ability to detect low-abundance lipid molecular species improves. An update of technical developments within the field of lipidomics from 2006 to the present is provided, along with a brief discussion of its applications in biomarker and drug development.",
keywords = "Biomarker, Drug discovery, Electrospray ionization mass spectrometry, Lipidomics, Pharmacolipidomics, Shotgun lipidomics",
author = "Xianlin Han",
year = "2007",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "586--591",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "6",

}

TY - JOUR

T1 - An update on lipidomics

T2 - Progress and application in biomarker and drug development

AU - Han, Xianlin

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Substantial progress has been made in the application of lipidomics in biomarker discovery and drug development, as well as in a variety of other areas. In particular, the number of published studies reporting the quantitation and analysis of low-abundance lipid molecular species has greatly increased. It can be anticipated that many of the biochemical mechanisms underlying metabolic syndromes and other lipid-related diseases will be identified through these methods. Importantly, lipid markers diagnostic of the onset, progression, or severity of these diseases as well as evaluation of drug efficacy and safety will be discovered as the ability to detect low-abundance lipid molecular species improves. An update of technical developments within the field of lipidomics from 2006 to the present is provided, along with a brief discussion of its applications in biomarker and drug development.

AB - Substantial progress has been made in the application of lipidomics in biomarker discovery and drug development, as well as in a variety of other areas. In particular, the number of published studies reporting the quantitation and analysis of low-abundance lipid molecular species has greatly increased. It can be anticipated that many of the biochemical mechanisms underlying metabolic syndromes and other lipid-related diseases will be identified through these methods. Importantly, lipid markers diagnostic of the onset, progression, or severity of these diseases as well as evaluation of drug efficacy and safety will be discovered as the ability to detect low-abundance lipid molecular species improves. An update of technical developments within the field of lipidomics from 2006 to the present is provided, along with a brief discussion of its applications in biomarker and drug development.

KW - Biomarker

KW - Drug discovery

KW - Electrospray ionization mass spectrometry

KW - Lipidomics

KW - Pharmacolipidomics

KW - Shotgun lipidomics

UR - http://www.scopus.com/inward/record.url?scp=36549033826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549033826&partnerID=8YFLogxK

M3 - Review article

C2 - 18041669

AN - SCOPUS:36549033826

VL - 9

SP - 586

EP - 591

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 6

ER -